Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman(Massachusetts General Hospital), Liang Chen(Dana-Farber Cancer Institute), Xiaohong Tan(Dana-Farber Cancer Institute), Katherine Crosby(Cell Signaling Technology (United States)), Alexander R. Guimarães(Athinoula A. Martinos Center for Biomedical Imaging), Rabi Upadhyay(Athinoula A. Martinos Center for Biomedical Imaging), Michel Maira(Novartis Institutes for BioMedical Research), Kate McNamara(Dana-Farber/Harvard Cancer Center), Samanthi A. Perera(Dana-Farber/Harvard Cancer Center), Youngchul Song(Massachusetts General Hospital), Lucian R. Chirieac(Brigham and Women's Hospital), Ramneet Kaur(Massachusetts General Hospital), Angela Lightbown(Cell Signaling Technology (United States)), Jessica Simendinger(Cell Signaling Technology (United States)), Timothy Li(Beth Israel Deaconess Medical Center), Robert F. Padera(Brigham and Women's Hospital), Carlos Garcı́a-Echeverrı́a(Novartis Institutes for BioMedical Research), Ralph Weissleder(Harvard University), Umar Mahmood(Massachusetts General Hospital), Lewis C. Cantley(Center for Systems Biology), Kwok‐Kin Wong(Dana-Farber Cancer Institute)
Cited by 1,328Open Access
Abstract
Related Papers
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity
Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al.|Molecular Cancer Therapeutics|2008|1.1k